| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | US6238878 FVlla/TF activity inhibiting compounds |
| 05/29/2001 | US6238664 Process for stabilizing proteins |
| 05/29/2001 | US6238660 Interleukin-12 inducer and medical composition |
| 05/29/2001 | US6238645 Methods of oxygenating tissues |
| 05/29/2001 | CA2195923C Azetidines |
| 05/29/2001 | CA2127530C Metal complexes of water soluble texaphyrins |
| 05/25/2001 | WO2001036686A2 Genomic polymorphism for predicting therapeutic response |
| 05/25/2001 | WO2001036674A2 Diagnostic methods for detection of prostate disorders |
| 05/25/2001 | WO2001036646A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | WO2001036645A2 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036642A1 HUMAN MONOCLONAL ANTIBODIES AGAINST TGF-βII RECEPTOR AND MEDICINAL USE THEREOF |
| 05/25/2001 | WO2001036641A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 05/25/2001 | WO2001036640A2 Human fgf-21 gene and gene expression products |
| 05/25/2001 | WO2001036638A2 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | WO2001036633A1 Novel protein and dna thereof |
| 05/25/2001 | WO2001036624A1 High order nucleic acid based structures |
| 05/25/2001 | WO2001036489A2 Erythropoietin forms with improved properties |
| 05/25/2001 | WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 05/25/2001 | WO2001036441A1 Antisense modulation of src-3 expression |
| 05/25/2001 | WO2001036436A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036420A1 Tricyclic azaindolizine derivatives having an spla2- inhibiting effect |
| 05/25/2001 | WO2001036419A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 05/25/2001 | WO2001036417A1 New use and novel n-azabicyclo-amide derivatives |
| 05/25/2001 | WO2001036407A1 Novel amidine derivatives, preparation and use thereof as medicines |
| 05/25/2001 | WO2001036402A1 Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| 05/25/2001 | WO2001036401A1 Solid state forms of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036395A1 Triazoles as farnesyl transferase inhibitors |
| 05/25/2001 | WO2001036390A1 Indazolyloxy propanolamines for improving livestock production |
| 05/25/2001 | WO2001036385A1 Hydroxyethoxybenzamide derivatives and drugs containing the same |
| 05/25/2001 | WO2001036376A1 Novel phenylalanine derivatives |
| 05/25/2001 | WO2001036360A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035980A1 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS |
| 05/25/2001 | WO2001035975A2 Treatment of subnormal bone mineral density |
| 05/25/2001 | WO2001035971A1 Whitening compositions for oral administration |
| 05/25/2001 | WO2001035970A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | WO2001035962A1 Solutions containing epinastine |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035959A1 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders |
| 05/25/2001 | WO2001035955A1 Benzene derivatives and use thereof as drugs |
| 05/25/2001 | WO2001035941A2 Novel composition based on a thiazolidinedione and metformin and use |
| 05/25/2001 | WO2001035933A2 A method of microencapsulation |
| 05/25/2001 | WO2001035920A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | WO2001035901A2 Use of enzymes for skin expansion |
| 05/25/2001 | WO2001035899A2 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 05/25/2001 | WO2000078330A3 Adenosine diphosphatase and activators thereof and their medical uses |
| 05/25/2001 | WO2000075278A3 Gene encoding nade, p75ntr-associated cell death executor and uses thereof |
| 05/25/2001 | WO2000072833A3 Pharmaceutical preparations for inhibiting sphingomyelinase |
| 05/25/2001 | WO2000071114A8 Salts of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate] |
| 05/25/2001 | WO2000059489A3 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 05/25/2001 | WO2000032555A8 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 05/25/2001 | WO2000010588A3 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 05/25/2001 | WO1999033841B1 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 05/25/2001 | CA2720361A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2392103A1 Human fgf-21 gene and gene expression products |
| 05/25/2001 | CA2392059A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 05/25/2001 | CA2391908A1 Novel polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391885A1 Polypeptides and nucleic acids encoding same |
| 05/25/2001 | CA2391622A1 Inhibiting gene expression with dsrna |
| 05/25/2001 | CA2391603A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | CA2391598A1 Novel amidine derivatives, preparation and use thereof as medicines |
| 05/25/2001 | CA2391429A1 Solid state forms of 5-¬¬6-¬(2-fluorophenyl)methoxy|-2-naphthalenyl|methyl|-2,4-thiazolidinedione |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | CA2391403A1 Novel protein and dna thereof |
| 05/25/2001 | CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors |
| 05/25/2001 | CA2391084A1 High order nucleic acid based structures |
| 05/25/2001 | CA2391080A1 Erythropoietin forms with improved properties |
| 05/25/2001 | CA2390431A1 Treatment of subnormal bone mineral density |
| 05/25/2001 | CA2390051A1 Thymidylate synthase polymorphism for predicting chemotherapeutic response |
| 05/25/2001 | CA2390031A1 Double-stranded rna receptor (dsrna-r) and methods relating thereto |
| 05/25/2001 | CA2389862A1 Human monoclonal antibody against tgf-.beta.ii receptor and medicinal use thereof |
| 05/25/2001 | CA2389851A1 Human igm antibodies to chemokine receptors |
| 05/25/2001 | CA2389604A1 New use and novel n-azabicyclo-amide derivatives |
| 05/25/2001 | CA2388846A1 Novel composition and use |
| 05/25/2001 | CA2388807A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2387809A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 05/24/2001 | CA2290316A1 Novel source of eleutherobin and related antimitotic diterpenes |
| 05/23/2001 | EP1101757A1 Heterocyclic compounds as tachykinin receptor antagonists |
| 05/23/2001 | EP1101112A2 Leptin-mediated gene-induction |
| 05/23/2001 | EP1100964A1 Gene sequence variances with utility in determining the treatment of disease |
| 05/23/2001 | EP1100962A1 Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases |
| 05/23/2001 | EP1100961A1 Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases |
| 05/23/2001 | EP1100945A2 Latency-active regulatory sequences of herpesviruses and lantency-inactive herpesviruses for gene transfer |
| 05/23/2001 | EP1100916A2 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal |
| 05/23/2001 | EP1100913A1 Mekk1 serine threonine kinases -interacting fha forkhead associated domain protein 1 (mif1) |
| 05/23/2001 | EP1100909A2 Dna replication- and repair-associated proteins |
| 05/23/2001 | EP1100907A2 Human cytoskeletal proteins |
| 05/23/2001 | EP1100896A1 Dna encoding snorf33 receptor |
| 05/23/2001 | EP1100894A2 Short oligonucleotides for the inhibition of vegf expression |
| 05/23/2001 | EP1100882A1 Human protein kinase h2lau20 |
| 05/23/2001 | EP1100879A1 Pneumococcal nrdg protein |
| 05/23/2001 | EP1100878A2 Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy |
| 05/23/2001 | EP1100875A2 Inhibition of graft versus host disease |
| 05/23/2001 | EP1100871A2 Method for preparing a cartilage cell suspension |
| 05/23/2001 | EP1100826A1 Isoforms of human calcium sensing receptor |
| 05/23/2001 | EP1100824A1 Compounds with growth hormone releasing properties |